Key takeaways
- Gastric inhibitory polypeptide (GIP) is a natural gut hormone that helps regulate blood sugar.
- When combined with glucagon-like peptide-1 (GLP-1) in medications like Mounjaro and Zepbound (tirzepatide), GIP can significantly boost weight loss and improve blood sugar management.
- Dual GIP and GLP-1 receptor agonist medications are approved for some adults with type 2 diabetes, weight management, and moderate to severe obstructive sleep apnea.
Gastric inhibitory polypeptide (GIP) is a hormone that helps regulate blood sugar. New medications that target both GIP and GLP-1 receptors help treat type 2 diabetes and obesity.
GIP stands for gastric inhibitory polypeptide, which is also referred to as glucose-dependent insulinotropic polypeptide.
Like GLP-1, GIP is an incretin hormone. These are natural chemical messengers released by your gut cells whenever you eat food. Their main job is to tell your body that nutrients are on the way and to prepare your metabolism accordingly.
GIP drugs are synthetic versions of this natural hormone that work in three key ways:
- They signal your pancreas to release insulin. Your pancreas has a built-in safety switch that only activates when your blood sugar is high, minimizing the risk of a sudden, dangerous crash.
- They target specific receptors in the brain’s satiety centers. This signals your body that you’re full — curbing your appetite and quieting “food noise” (thoughts about food).
- They act directly on adipose (fat) tissue, improving how your body stores and clears fat from your bloodstream and preventing it from accumulating in harmful places, such as your liver. This ultimately boosts your overall insulin sensitivity.
There are currently no widely prescribed GIP-only medications on the market. Researchers discovered that GIP works best when combined with GLP-1. These dual-action medications are known as dual GIP/GLP-1 receptor agonists.
Drugs that utilize the GIP pathway are
- Type 2 diabetes management: They dramatically improve blood sugar management, lower HbA1c levels, and help the pancreas function efficiently.
- Chronic weight management: They’re prescribed for adults with obesity (a BMI of 30 or higher), or those who are overweight (a BMI of 27 or higher) with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
- Obstructive sleep apnea: The Food and Drug Administration (FDA) has approved tirzepatide for moderate to severe sleep apnea in adults with obesity. It has been shown to significantly reduce nightly breathing disruptions by targeting underlying metabolic factors and promoting weight loss.
There is currently only one approved generic drug molecule that utilizes the GIP pathway. It’s sold under two different brand names depending on the specific condition it’s being used to treat.
Next-generation triple agonist drugs, which combine GIP, GLP-1, and a third hormone, glucagon (such as the experimental drug retatrutide), are advancing through clinical trials to offer even greater metabolic benefits.
While GIP and GLP-1 are both gut hormones that work together to help manage blood sugar and enhance weight loss, they’re not identical. Think of them as two different puzzle pieces that fit together to optimize metabolic health.
| Feature | GIP | GLP-1 |
|---|---|---|
| Primary source | secreted by K cells in the upper intestine | secreted by L cells in the lower intestine |
| Stomach digestion | doesn’t have a major impact on slowing down the stomach’s physical emptying process | significantly slows gastric emptying, keeping food in your stomach longer so you feel physically full |
| Low blood sugar response | protects against low blood sugar by increasing glucagon secretion if levels drop too low | suppresses glucagon secretion during high blood sugar to keep levels from spiking further |
| Direct action on fat metabolism | actively interacts with fat cells to encourage healthy, efficient fat storage and clearance | promotes fat breakdown indirectly via the central nervous system |
When taken alone in
The GIP component amplifies the blood-sugar-lowering and weight-loss effects of GLP-1, enabling patients to achieve remarkable results.
While GLP-1 medications paved the way for modern metabolic medicine, drugs that incorporate GIP represent the next major evolution.
By mimicking two natural gut hormones instead of just one, dual-action medications like tirzepatide (Mounjaro or Zepbound) offer a highly effective, multi-targeted approach to health. They simultaneously regulate blood sugar, reduce appetite, and improve the body’s utilization of fat tissue.
Whether used to treat type 2 diabetes, support long-term weight management, or address related conditions like obstructive sleep apnea, GIP drugs are a promising tool for transforming metabolic wellness.
Disclaimer: While Healthline strives for factual, comprehensive, and current information, this article is not a substitute for a licensed healthcare professional’s expertise. Always consult a doctor before taking or discontinuing any medication. Drug information is subject to change and may not cover all uses, directions, precautions, warnings, interactions, reactions, or adverse effects. The lack of a warning does not guarantee a drug’s safety, effectiveness, or appropriateness for all patients or specific uses. Learn more about our approach to content integrity.